IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $44.7M fell 2.0% year over year, behind the +26.9% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 13.0% of revenue in FY2025, down 1024.0 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -2.0% toward the trailing-twelve-month pace of +26.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$44.7M+124.0% QoQ
Last fiscal yearDec 2025
$28.45M+139.2% YoY
LTMMar 2026
$27.53M+26.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.0%——
1 year+139.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
28.45M USD
Year-over-year change
+139.2%
4-year CAGR
+9.2%

Net Change in Cash vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 net change in cash of $27.53M is the 8th largest of the 9 companies compared; the peer median is $48.36M.
  • Its year-over-year change of +26.9% is the 8th highest of 9, against a peer median of +239.7%.
  • Net change in cash amounts to 12.2% of revenue for IDYA, versus a peer median of 97.8%.
IDYA Competitors Peer median
Net Change in Cash for IDYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M +3223.9%—91.4%
RVMDRevolution Medicines, Inc.LTM Jun 2026$413.94M +226.5%——
COGTCogent Biosciences, Inc.LTM Jun 2026$53.57M +36.0%——
ERASErasca, Inc.LTM Sep 2026$48.73M +3523.0%——
VSTMVerastem, Inc.LTM Mar 2026$47.98M +36.3%+28.9%96.8%
TNGXTango Therapeutics, Inc.LTM Sep 2026$28.07M +440.8%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$27.89M +253.0%—98.8%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$27.53M +26.9%—12.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$19.32M -224.2%—115.6%
Peer median (excluding IDYA) $48.36M+239.7%+28.9%97.8%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
Deferred Income Tax00000
Stock-Based Compensation8.24M11.63M18.49M34.75M46.12M
Change in Working Capital(17.81M)(41.56M)(13.21M)11.55M1.87M
Accounts Receivables774K892K193K15K0
Inventory3.79M0000
Accounts Payables1.17M1.86M2.64M8.28M2.7M
Other Working Capital(23.54M)(44.31M)(16.04M)3.25M(829K)
Other Non-Cash Items1.83M(695K)(11.55M)(23.23M)(9.98M)
Operating Cash Flow(55.78M)(87.18M)(115.22M)(247.58M)(71.1M)
Capital Expenditures(2.64M)(3.44M)(2.37M)(3.86M)(2.37M)
Acquisitions (Net)67.02M33.4M000
Purchases of Investments(315M)(255.81M)(595.98M)(1.19B)(607.89M)
Sales of Investments247.97M225.85M439.89M692.61M680.23M
Other Investing Activities(67.02M)(33.4M)000
Investing Cash Flow(69.67M)(33.4M)(158.46M)(502.56M)69.98M
Debt Repayment00000
Common Stock Issued143.25M94.96M309.76M654.23M29.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.2M2.2M10.77M13.92M0
Financing Cash Flow145.45M97.17M362.72M677.55M29.78M
Effect of Forex Changes0000(210K)
Net Change in Cash20.01M(23.41M)89.04M(72.59M)28.45M
Free Cash Flow(58.42M)(90.62M)(117.59M)(251.44M)(73.47M)

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.